相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Irfan A. Asangani et al.
MOLECULAR CELL (2013)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells
Philipp Baumann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
Amir A. Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis
E. Kerr et al.
CELL DEATH AND DIFFERENTIATION (2012)
The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
Miguel Lemaire et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Donna M. Weber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma
Xufeng Chen et al.
MOLECULAR CANCER RESEARCH (2012)
Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials
H. Miles Prince
LEUKEMIA & LYMPHOMA (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
Arsenic Trioxide Exerts Antimyeloma Effects by Inhibiting Activity in the Cytoplasmic Substrates of Histone Deacetylase 6
Xiaoyan Qu et al.
PLOS ONE (2012)
Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma
Kinga A. Kocemba et al.
PLOS ONE (2012)
The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies
Philippe Moreau
SEMINARS IN HEMATOLOGY (2012)
Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma
Yuka Aoki et al.
GENOME MEDICINE (2012)
Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma
Xiaosong Wu et al.
NEOPLASIA (2012)
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Herve Avet-Loiseau et al.
BLOOD (2011)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J. Harrison et al.
BLOOD (2011)
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo et al.
BLOOD (2011)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Nikhil C. Munshi et al.
BLOOD (2011)
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
V. Cheriyath et al.
BRITISH JOURNAL OF CANCER (2011)
Guidelines for the diagnosis and management of multiple myeloma 2011
Jennifer M. Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
Amberly Moreno-Bost et al.
CYTOTHERAPY (2011)
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma
Stefan Wilop et al.
EPIGENETICS (2011)
CpG island chromatin A platform for gene regulation
Neil P. Blackledge et al.
EPIGENETICS (2011)
CpG islands and the regulation of transcription
Aimee M. Deaton et al.
GENES & DEVELOPMENT (2011)
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
Shuhong Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
DNA Methylation and Demethylation in Mammals
Zhao-xia Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation
Wen Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Mario Federico et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
OPERating ON Chromatin, a Colorful Language where Context Matters
Kathryn E. Gardner et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
A Peek into the Complex Realm of Histone Phosphorylation
Taraswi Banerjee et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
Tiffany Khong et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Eric Sanchez et al.
LEUKEMIA RESEARCH (2011)
HDACs link the DNA damage response, processing of double-strand breaks and autophagy
Thomas Robert et al.
NATURE (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance
Carmen Stanganelli et al.
ANNALS OF HEMATOLOGY (2010)
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
Monica Galli et al.
ANNALS OF HEMATOLOGY (2010)
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
Elke De Bruyne et al.
BLOOD (2010)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
Gareth Morgan
BLOOD REVIEWS (2010)
Multiple myeloma: biology of the disease
Anuj Mahindra et al.
BLOOD REVIEWS (2010)
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585
Thorsten Stuehmer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The potential role of epigenetic therapy in multiple myeloma
Emma M. Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
Sonja Mandl-Weber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells
Choon-Kee Lee et al.
CANCER LETTERS (2010)
DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors
Bodour Salhia et al.
CANCER RESEARCH (2010)
The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
Zainab Jagani et al.
CANCER RESEARCH (2010)
Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice
Amitabha Mazumder et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia
Eleftheria Hatzimichael et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interieukin-6 receptor signaling and repression of miR-19a and miR-19b
Katia Todoerti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Methylation status of nine tumor suppressor genes in multiple myeloma
Esteban Braggio et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Polycomb Target Genes Are Silenced in Multiple Myeloma
Antonia Kalushkova et al.
PLOS ONE (2010)
DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer
Amy Sharma et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2010)
Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeutics
Ruthrotha B. Selvi et al.
Biotechnology Journal (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma
E. Jost et al.
CANCER LETTERS (2009)
Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Sarah Deleu et al.
CANCER RESEARCH (2009)
Differential repetitive DNA methylation in multiple myeloma molecular subgroups
Valentina Bollati et al.
CARCINOGENESIS (2009)
Epigenetic mechanisms in mammals
J. K. Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
Masanori Nojima et al.
CLINICAL CANCER RESEARCH (2009)
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma
Guanghua Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma
Fabricio de Carvalho et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma
Ken-ichi Kitazoe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
Shuang Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Protein Arginine Methylation in Mammals: Who, What, and Why
Mark T. Bedford et al.
MOLECULAR CELL (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models
S. Deleu et al.
LEUKEMIA (2009)
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity
Andrew Xiao et al.
NATURE (2009)
Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions
Peter J. Cook et al.
NATURE (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Veronique Baud et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Linking DNA methylation and histone modification: patterns and paradigms
Howard Cedar et al.
NATURE REVIEWS GENETICS (2009)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar et al.
MAYO CLINIC PROCEEDINGS (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Jotin Marango et al.
BLOOD (2008)
Genome-wide transcriptional response to 5-aza-2 '-deoxycytidine and trichostatin a in multiple myeloma cells
Gerwin Heller et al.
CANCER RESEARCH (2008)
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival
Elke De Bruyne et al.
CLINICAL CANCER RESEARCH (2008)
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Peter Gimsing et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Marina Tshuikina et al.
EXPERIMENTAL HEMATOLOGY (2008)
The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma
Tiffany Khong et al.
HAEMATOLOGICA (2008)
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways
Quanyi Lu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling
Rentian Feng et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Lysine acetylation: Codified crosstalk with other posttranslational modifications
Xiang-Jiao Yang et al.
MOLECULAR CELL (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Nucleoside analogs: molecular mechanisms signaling cell death
B. Ewald et al.
ONCOGENE (2008)
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma
C. S. Chim et al.
LEUKEMIA (2007)
Genetic events in the pathogenesis of multiple myeloma
W. J. Chng et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
Rentian Feng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
Crescent R. Isham et al.
BLOOD (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator
Elaine M. Hurt et al.
CANCER BIOLOGY & THERAPY (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma
Y-F Song et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
DNA methylation and histone modifications: teaming up to silence genes
F Fuks
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
TE Fandy et al.
NEOPLASIA (2005)
The key to development: interpreting the histone code?
R Margueron et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors
J Reddy et al.
ONCOGENE (2005)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies
S Seidl et al.
CANCER (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
L Catley et al.
BLOOD (2003)
Structure, function and evolution of CpG island promoters
F Antequera
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma -: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events
L Quintanilla-Martinez et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway
D Lavelle et al.
LEUKEMIA RESEARCH (2003)
DNA methylation patterns and epigenetic memory
A Bird
GENES & DEVELOPMENT (2002)
Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression
D Lavelle et al.
AMERICAN JOURNAL OF HEMATOLOGY (2001)
The DNA methyltransferases of mammals
TH Bestor
HUMAN MOLECULAR GENETICS (2000)
分享论文
